Prognostic significance of the mad1l1 1673 g:a polymorphism in ovarian adenocarcinomas

Bandala-Jacques, Antonio; Hernández-Cruz, Irwin A.; Castro-Hernández, Clementina; Díaz-Chávez, José; Arriaga-Canon, Cristian; Barquet-Muñoz, Salim A.; Prada-Ortega, Diddier G.; Cantú-de León, David; Herrera, Luis A..
Rev. invest. clín ; 72(6): 372-379, Nov.-Dec. 2020. tab, graf
Artículo en Inglés | LILACS | ID: biblio-1289732

Documentos relacionados

  1. Prognostic Significance of the MAD1L1 1673 G: A Polymorphism in Ovarian Adenocarcinomas.
  2. Five-year survival decreases over time in patients with BRCA-mutated ovarian cancer: a systemic review and meta-analysis.
  3. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors.
  4. Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
  5. Ovarian RASoma With Mesonephric-like Adenocarcinoma and Mixed Mullerian Components: A Case Report With Molecular Analysis Demonstrating Multidirectional Mullerian Differentiation.
  6. A Prognostic Model Based on Metabolism-Related Genes for Patients with Ovarian Cancer.
  7. Improving the Lives of Women With Ovarian Cancer.
  8. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
  9. Pattern A endocervical adenocarcinomas with ovarian metastasis are indolent and molecularly distinct from destructively invasive adenocarcinomas.
  10. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with <i>BRCA</i> mutated advanced high grade serous ovarian cancer: 10 year survival analysis.